FDA Approves Decnupaz for Blastic Plasmacytoid Dendritic Cell Neoplasm

Photo by Am / Unsplash

FDA Published June 2, 2026 Medically reviewed June 2, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note the need for premedication and monitoring for veno-occlusive disease, hepatotoxicity, and edema with Decnupaz.

The FDA has approved Decnupaz (decnupaz) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy. Decnupaz is a CD123-directed antibody and alkylating agent conjugate, representing a targeted therapy for this disease. The approval provides a new treatment option for patients with BPDCN, which historically has had limited therapeutic options. The recommended dose is 0.045 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity. Premedication with corticosteroids, antihistamines, and antipyretics is required to reduce the risk of infusion-related reactions. Clinicians should be aware of warnings for veno-occlusive disease, hepatotoxicity, infusion-related reactions, and edema, which require dose modifications or discontinuation.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Decnupaz is a CD123-directed antibody and alkylating agent conjugate. The antibody binds to CD123-expressing cells, and after internalization, the alkylating agent is released to cause DNA damage and cell death.

Indication & Patient Population

Decnupaz is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Dosing & Administration

The recommended dose is 0.045 mg/kg intravenously over approximately 15-30 minutes once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Premedicate with a corticosteroid (e.g., dexamethasone 8 mg twice daily) on the day prior to infusion, and with a corticosteroid (dexamethasone 8 mg IV), antihistamine (diphenhydramine 25-50 mg IV), and antipyretic (acetaminophen 325-650 mg oral) at least 30-60 minutes prior to infusion. Dose modifications are required for adverse reactions including veno-occlusive disease (permanently discontinue), increased AST/ALT or bilirubin (delay dosing), infusion-related reactions (interrupt, stop, or discontinue based on grade), edema (delay and consider dose reduction), and other Grade 3-4 non-hematologic adverse reactions (delay or discontinue).

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Warnings include veno-occlusive disease (VOD), hepatotoxicity (increased AST/ALT or bilirubin), infusion-related reactions, and edema. For VOD of any grade, permanently discontinue Decnupaz. For AST or ALT >2.5 x ULN, delay dosing until ≤2.5 x ULN. For total bilirubin >1.5 x ULN, delay dosing until ≤1.5 x ULN. For infusion-related reactions, manage according to grade (interrupt, stop, or permanently discontinue). For edema, manage with diuretics and delay dosing; consider dose reduction if delayed >2 weeks. No contraindications are listed in the label.

Place in Therapy

Decnupaz is a targeted therapy for adult patients with BPDCN, a rare disease with limited treatment options. It is administered intravenously every 3 weeks with required premedication. Monitoring for VOD, hepatotoxicity, infusion reactions, and edema is essential.

Study Details

Study typeFda approval

PublishedMay 2026

View Original Abstract ↓

1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ( 1 )